BIOVIC B — Biovica International AB Share Price
0.000.00%
Last trade - 00:00- SEK82.14m
- SEK62.38m
- SEK8.62m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.9 | ||
| Price to Tang. Book | 4.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.53 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -183.45% | ||
| Return on Equity | -125.31% | ||
| Operating Margin | -995.93% | ||
Financial Summary
| Year End 30th Apr | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 2.08 | 2.04 | 3.38 | 7.29 | 8.62 | 31.5 | 81 | 38.83% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
Directors
- Lars Holmqvist NEC (62)
- Anders Rylander CEO (51)
- Cecilia Driving CFO (50)
- Robert Dann SVP (59)
- Henrik Winther SVP (55)
- Tomas Andersson VOP (61)
- Joakim Arwidson VPR (53)
- Helle Fisker VPR (52)
- Otti Gref VRD
- Adam Germunder OTH (37)
- Annika Berg IND (58)
- Marie-louise Fjallskog IND (57)
- Maria Holmlund IND (65)
- Jarl Jungnelius IND (70)
- Henrik Osvald IND (62)
- Jesper Soderqvist IND (55)
- Last Annual
- April 30th, 2025
- Last Interim
- April 30th, 2025
- Incorporated
- December 29th, 2008
- Public Since
- March 29th, 2017
- No. of Employees
- 27
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 97,786,384
- Address
- Dag Hammarskjolds vag 54B, UPPSALA, 752 37
- Web
- https://biovica.com/
- Phone
- +46 184444830
- Contact
- Anders Rylander
- Auditors
- Grant Thornton Sweden AB
Upcoming Events for BIOVIC B
Q1 2026 Biovica International AB Earnings Release
Biovica International AB Annual Shareholders Meeting
Q2 2026 Biovica International AB Earnings Release
Similar to BIOVIC B
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
What is the Biovica International AB share price?
As of Today at 19:37 UTC, shares in Biovica International AB are trading at SEK0.84. This share price information is delayed by 15 minutes.
How has the Biovica International AB share price performed this year?
Shares in Biovica International AB last closed at SEK0.84 and the price had moved by -68.83% over the past 365 days. In terms of relative price strength the Biovica International AB share price has underperformed the FTSE Global All Cap Index by -70.58% over the past year.
What are the analyst and broker recommendations for Biovica International AB?
The overall consensus recommendation for Biovica International AB is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Biovica International AB dividend yield?
Biovica International AB does not currently pay a dividend.
Does Biovica International AB pay a dividend?
Biovica International AB does not currently pay a dividend.
When does Biovica International AB next pay dividends?
Biovica International AB does not currently pay a dividend.
How do I buy Biovica International AB shares?
To buy shares in Biovica International AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biovica International AB?
As of the previous close price of SEK0.84, shares in Biovica International AB had a market capitalisation of SEK82.14m.
Where are Biovica International AB shares listed?
Here are the trading details for Biovica International AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: BIOVIC B
What kind of share is Biovica International AB?
Based on an overall assessment of its quality, value and momentum Biovica International AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biovica International AB share price forecast for 2025?
The analyst consensus target price for shares in Biovica International AB is SEK2.40. That is 185.71% above the last closing price of SEK0.84.
Analysts covering Biovica International AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.32 for the next financial year.
Find out moreWhat is the trend in the Biovica International AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biovica International AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -57.65%.
As of the last closing price of SEK0.84, shares in Biovica International AB were trading -49.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biovica International AB PE Ratio?
The Biovica International AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biovica International AB?
Biovica International AB's management team is headed by:
- Lars Holmqvist - NEC
- Anders Rylander - CEO
- Cecilia Driving - CFO
- Robert Dann - SVP
- Henrik Winther - SVP
- Tomas Andersson - VOP
- Joakim Arwidson - VPR
- Helle Fisker - VPR
- Otti Gref - VRD
- Adam Germunder - OTH
- Annika Berg - IND
- Marie-louise Fjallskog - IND
- Maria Holmlund - IND
- Jarl Jungnelius - IND
- Henrik Osvald - IND
- Jesper Soderqvist - IND